PBLA:NSD-Panbela Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.34

Change

-0.03 (-7.73)%

Market Cap

USD 1.60M

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-46.00 (-4.21%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+2.99 (+0.65%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

-0.83 (-0.31%)

USD 34.90B
ARGX argenx NV ADR

-8.74 (-1.65%)

USD 32.16B
MRNA Moderna Inc

-0.20 (-0.31%)

USD 25.25B
BGNE BeiGene Ltd

+8.00 (+3.97%)

USD 22.45B
SMMT Summit Therapeutics PLC

+2.09 (+9.54%)

USD 17.92B
RPRX Royalty Pharma Plc

N/A

USD 16.34B
UTHR United Therapeutics Corporatio..

+2.28 (+0.64%)

USD 15.71B
PCVX Vaxcyte Inc

+3.54 (+3.16%)

USD 14.50B

ETFs Containing PBLA

GREK Global X MSCI Greece ETF 4.86 % 0.59 %

+0.94 (+2.21%)

USD 0.20B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -98.14% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.14% 1% F 1% F
Trailing 12 Months  
Capital Gain -98.67% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.67% 1% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 68.38% 87% B+ 93% A
Dividend Return 68.38% 87% B+ 92% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,973.37% 7% C- 2% F
Risk Adjusted Return 3.47% 57% F 41% F
Market Capitalization 1.60M 2% F 2% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector